Healio Launches Healio AI

Healio has launched Healio AI, a HIPAA-compliant clinical information platform designed to deliver verified, evidence-based insights to health care professionals. The company, which marks 125 years as a medical news provider, said the tool updates daily and is intended to support decision-making at the point of care.

The free platform aggregates content from PubMed-indexed research, enrolling clinical trials, peer-reviewed studies, FDA data, more than 140 global medical meetings and Healio’s editorial archives. According to Healio, the system is built to surface concise, relevant information on diagnostics, treatment options, and emerging medical evidence, with the goal of augmenting clinical decision pathways and potentially accelerating time to treatment.

“Millions of health care professionals across more than 20 areas of specialty turn to Healio for trusted news, clinical updates and expert insights,” said Matthew Holland, chief operating officer at Healio. “Healio AI delivers the same quality content our users depend on in a more customized and consolidated format so they can stay focused on what matters most – treating people.”

The launch comes amid growing adoption of AI in clinical practice. A 2025 American Medical Association survey cited by the company reported that two-thirds of physicians are currently using AI tools, and 68% view AI as beneficial for patient care, reflecting expanding demand for trustworthy, up-to-date clinical information sources.

“Global medical knowledge is expanding faster than ever before,” said Hansa Bhargava, MD, Healio’s chief clinical strategy and innovation officer. “Clinicians are challenged to keep up with the daily updates on therapies, regulations and health guidance. Healio AI can give them the most current information in seconds.”

Healio positions the new platform as an extension of its existing clinical news, education, and specialty-focused resources, spanning more than 20 medical disciplines.

solli’s Final Thoughts

Generative AI’s move into point-of-care information delivery signals a shift in how clinicians will access and interpret medical evidence. As more trusted publishers deploy similar tools, pharma media may need to adapt by structuring data for AI retrieval, tightening editorial rigor, and accelerating reporting cycles. The broader trend suggests an environment where verified, machine-readable clinical intelligence becomes an expectation—raising the stakes for accuracy, transparency and speed across medical communications.